

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and Hywel Dda University Health Board

Document Number GB-74466

Date of Preparation Feb 2026

Project title	Project 50 CLEAR programme - Hwyl Dda HB
Aims and Objectives	Optimise the identification and management of Severe Asthma patients. Increase number of suspected Severe Asthma patient reviews Increase uptake / initiation of biologics where appropriate to do so Reduction in OCS usage in patients identified Improvement in symptoms / ACQ score) in all patients identified Accelerating SA patient pathway timelines – time to MDT / appropriate treatment.
Anticipated benefits	It is expected that this project will support the following groups in the following ways: Patient: Optimised Treatment: Appropriately being identified as a patient who may benefit from alternative treatment options for severe asthma. Appropriate initiation and optimisation of medicines by Specialists in-line with local and national guidelines. Fewer Hospital Visits: Early, customised interventions will likely lead to a reduction in non-elective admissions and readmissions, easing the burden on patients. Improved Care Quality: Patients may experience significant improvements in the quality of care they receive, potentially enhancing their quality of life. NHS: Decreased Waiting Times: The project aims to reduce waiting times for specialist consultations, improving patient flow. Improved Care Quality: The overall quality of care for patients with severe asthma will be enhanced. Reduced Unplanned Admissions: In the longer term, the project is expected to improve patient flow and reduce the total number of unplanned admissions and inpatient bed days

	AstraZeneca: Align with Medical Mission: The project supports AstraZeneca's strategy to improve the lives of asthma patients, including those with severe asthma, by promoting early identification and optimal treatment. Optimised Medicine Use: The initiative supports the optimisation of medicines for the treatment of severe asthma. While the prescribing of AstraZeneca medicines may increase, the decision to prescribe will remain clinician-led in accordance with local protocols and guidelines. Share Best Practices: A successful project with demonstrable outcomes will allow AstraZeneca to share best practices across the UK healthcare system. Enhanced Reputation: The project is anticipated to improve AstraZeneca's corporate reputation and trust amongst the NHS and patients
Timeline	The project will commence on the 01 Dec 2025 and will continue for a duration of 12 months.
Contributions	The project will include the pooling of skills, experience and resources from both parties. AstraZeneca contribute to this project the total value of £46,494 including funding for additional clinical capacity, and AstraZeneca employee resource for project management and evaluation The NHS partner contributes a total value of £34,139.84 based on clinical time and project analysis. The NHS contribution does not include transfer of monies; it is based on cost of resource allocation. Full details of contributions are included in the agreed Joint Working Agreement with the NHS.

UK Non-Promotional Certificate

Document Number:

GB-74466

Document Name:

JW 379 - Hywel Dda University Health Board ESI

Product:

No Brand

Job Type:

Contributions

Joint Working

Certification Statement

I certify that I have examined the final form of the material to ensure that it complies with the ABPI Code of Practice. If this is certification of a meeting involving travel outside the UK, I certify that I have examined all the proposed arrangements for the meeting and that the arrangements are in accordance with the relevant regulations relating to advertising and the Code.

Role	Signature
I certify the above is true	Ella O'Connell Ella.Oconnell@astrazeneca.com Medical 14-May-2026 17:10:38 GMT+0000